What evidence exists for liver cancer alongside lung, breast, and kidney cancer?
Evidence links liver cancer to lung, breast, and kidney cancer primarily through shared advancements in biomarker technology and detection methods. Studies indicate that modern liquid biopsy tests can identify liver cancer with high specificity, comparable to other major cancer types. Additionally, long-term survival data for liver cancer shows marked improvement over the last two decades.
What the research says
A 2025 systematic review evaluated machine learning combined with circulating cell-free DNA for early cancer detection across multiple tumor types. This analysis included 29 studies on liver cancer alongside 34 on lung, 17 on breast, and 16 on pancreatic cancer. The review found that specificity for detecting cancer was consistently high between 94% and 99% for all tumor types studied. Sensitivity for early-stage disease ranged from 72% to 92% across these cancers 1.
Another review highlighted that classic biomarkers have evolved for each cancer type. For liver cancer, alpha-fetoprotein remains a key marker, while lung cancer relies on markers like carcinoembryonic antigen and neuron-specific enolase. Breast cancer detection focuses on hormone receptor status and HER2, and kidney cancer involves von Hippel–Lindau gene alterations. These distinct markers support targeted therapies and early detection for each specific cancer 2.
Survival outcomes for liver cancer have improved dramatically in recent years. In Taizhou, China, the 5-year relative survival rate for liver cancer rose from 5.56% between 2004 and 2023 to 37.32% between 2019 and 2023. This improvement suggests better early detection and treatment efficacy compared to earlier periods. Female patients consistently showed slightly higher survival rates than males in this population 4.
Advanced AI models are also being tested for treatment planning across different cancer sites. One framework trained on data from head and neck, prostate, breast, and lung cancers was able to predict radiation doses for liver cancer and whole brain cases with high accuracy. This suggests that geometric awareness in AI can bridge different anatomical domains, potentially improving personalized radiotherapy for liver cancer without needing separate models for each site 3.
What to ask your doctor
- What specific biomarkers, such as alpha-fetoprotein, are being tested for my liver cancer screening?
- How do the detection rates for liver cancer compare to other cancers like lung or breast cancer in my region?
- What is the current 5-year survival rate for liver cancer patients in my area?
- Can advanced AI models help plan my radiation treatment more effectively?
- Are there new liquid biopsy tests available that can detect liver cancer alongside other cancers?
This question is drawn from common patient questions about Gastroenterology and answered using cited medical research. We do not provide individualized advice.